238 related articles for article (PubMed ID: 21700625)
1. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
White AR;
J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
[TBL] [Abstract][Full Text] [Related]
2. The role of the pharmaceutical industry in meeting the public health threat of antibacterial resistance.
Bergström R
Drug Resist Updat; 2011 Apr; 14(2):77-8. PubMed ID: 21493123
[TBL] [Abstract][Full Text] [Related]
3. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
[TBL] [Abstract][Full Text] [Related]
4. Time for a change: addressing R&D and commercialization challenges for antibacterials.
Payne DJ; Miller LF; Findlay D; Anderson J; Marks L
Philos Trans R Soc Lond B Biol Sci; 2015 Jun; 370(1670):20140086. PubMed ID: 25918443
[TBL] [Abstract][Full Text] [Related]
5. Regulatory opportunities to encourage technology solutions to antibacterial drug resistance.
Finch R;
J Antimicrob Chemother; 2011 Sep; 66(9):1945-7. PubMed ID: 21700629
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.
Finch R; Hunter PA
J Antimicrob Chemother; 2006 Sep; 58 Suppl 1():i3-i22. PubMed ID: 17003063
[TBL] [Abstract][Full Text] [Related]
7. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
Årdal C; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
Clin Infect Dis; 2017 Oct; 65(8):1378-1382. PubMed ID: 29017240
[TBL] [Abstract][Full Text] [Related]
8. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
Kesselheim AS; Outterson K
Health Aff (Millwood); 2010 Sep; 29(9):1689-96. PubMed ID: 20820028
[TBL] [Abstract][Full Text] [Related]
9. The urgent need for new antibacterial agents.
Wise R;
J Antimicrob Chemother; 2011 Sep; 66(9):1939-40. PubMed ID: 21700627
[No Abstract] [Full Text] [Related]
10. Diagnostics as essential tools for containing antibacterial resistance.
Okeke IN; Peeling RW; Goossens H; Auckenthaler R; Olmsted SS; de Lavison JF; Zimmer BL; Perkins MD; Nordqvist K
Drug Resist Updat; 2011 Apr; 14(2):95-106. PubMed ID: 21398170
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
[TBL] [Abstract][Full Text] [Related]
13. Challenges of antibacterial discovery revisited.
Gwynn MN; Portnoy A; Rittenhouse SF; Payne DJ
Ann N Y Acad Sci; 2010 Dec; 1213():5-19. PubMed ID: 21058956
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial drug discovery: is it all downhill from here?
Projan SJ; Shlaes DM
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():18-22. PubMed ID: 15522036
[TBL] [Abstract][Full Text] [Related]
15. When will the genomics investment pay off for antibacterial discovery?
Mills SD
Biochem Pharmacol; 2006 Mar; 71(7):1096-102. PubMed ID: 16387281
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic research and development: business as usual?
Harbarth S; Theuretzbacher U; Hackett J;
J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
[TBL] [Abstract][Full Text] [Related]
17. Repairing the broken market for antibiotic innovation.
Outterson K; Powers JH; Daniel GW; McClellan MB
Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
[TBL] [Abstract][Full Text] [Related]
18. Balancing the benefits and costs of antibiotic drugs: the TREAT model.
Leibovici L; Paul M; Andreassen S
Clin Microbiol Infect; 2010 Dec; 16(12):1736-9. PubMed ID: 20673259
[TBL] [Abstract][Full Text] [Related]
19. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
20. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
